arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

PERRIGO Co plc

PRGO
$15.71 ▼ -0.14 (-0.88%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
55 Visible periods
34 Metrics
Peer-ranked Benchmarks
Price Chart
21
Health
Poor
Bearish
auto_awesome

Analytical Summary

PERRIGO Co plc faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.2B
Dividend Yield 1.85%
Revenue Growth -3.2% ↗
Op. Margin 2.3% ↗
ROIC 0.3% ↗
FCF / Share $0.49 ↗
Trailing P/E 29.1x
Price / Book 0.9x
FCF Yield 3.1%
Debt / Equity 1.31
info Valuation on last close. End-of-day price, Nov 5, 2026.

55-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.02B
↓ -3.2% —
Net Income Profit after all expenses
$-398.60M
↓ -6128.1% —
Operating Margin Operating profit as % of sales
2.3%
↑ +106.0% 8th
FCF / Share Free cash flow per share
$0.49
↑ +153.5% —
Long-Term Debt Long-term obligations
$3.28B
↓ -9.3% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability →
18
Returns ↓
17
Financial Health ↑
29
Cash Quality ↓
19

Dividend History

Dividend / share · sourced from SEC filings
$1.16 Latest / share
+5.5% YoY
+11.5% 11-yr CAGR

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 15 years · 55 quarters